Aerin Medical Inc.

Aerin Medical Inc. is a privately held, venture-backed medical device company founded in 2011 and headquartered in Mountain View, California, with additional offices in Austin, Texas. The company has approximately 101-200 employees. As of December 2024, Aerin Medical raised $32.48 million in Series G funding, co-led by KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation from Ares Capital.

Aerin Medical specializes in innovative, non-invasive treatment solutions for chronic nasal conditions, focusing on nasal airway obstruction (NAO) and chronic rhinitis. Their core products are the VivAer® Stylus for nasal airway obstruction and the RhinAer® Stylus (including the next-generation RhinAer+™ Stylus) for chronic rhinitis. These FDA-cleared devices utilize proprietary temperature-controlled or temperature- and impedance-controlled radiofrequency technology to deliver precise, tissue-sparing treatments that can be performed in a physician's office under local anesthetic.

Aerin Medical Inc. has a patent-litigation posture as a plaintiff, with one tracked case. The company is involved in "Aerin Medical Inc. v. Neurent Medical Ltd. et al.," filed in 2025-06-18 at the Patent Trial and Appeal Board (PTAB) of the USPTO. This indicates that Aerin Medical is asserting its intellectual property, likely challenging the validity of a competitor's patent or defending its own patents against a challenge. Neurent Medical is identified as a competitor by Owler.